AptaBio Therapeutics Inc.

KOSDAQ:A293780 Stock Report

Market Cap: ₩168.3b

AptaBio Therapeutics Past Earnings Performance

Past criteria checks 0/6

AptaBio Therapeutics's earnings have been declining at an average annual rate of -51.8%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 5430.6% per year.

Key information

-51.8%

Earnings growth rate

-50.5%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate5,430.6%
Return on equity-41.5%
Net Margin-694.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 29
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Feb 23
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Jan 01
Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Revenue & Expenses Breakdown

How AptaBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A293780 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,906-20,1705,54213,933
30 Jun 242,055-16,2363,78313,933
31 Mar 24942-11,0122,69314,019
31 Dec 23324-11,8673,91512,380
30 Sep 2353-13,2893,6269,240
31 Dec 2248-10,5652,7886,197

Quality Earnings: A293780 is currently unprofitable.

Growing Profit Margin: A293780 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A293780's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A293780's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A293780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A293780 has a negative Return on Equity (-41.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 11:02
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AptaBio Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Keunhee SeoSamsung Securities Co. Ltd.